文献速递烧伤

烧伤合并精神共病患者潜在药物相互作用的5年单中心回顾研究

A 5-year single-centre retrospective study of potential drug interactions in burns inpatients with psychiatric comorbidities.
PubMed 文献 · Burns · 2020-02-11

该研究利用国际烧伤损伤数据库识别成人区域烧伤病房5年内有精神共病的全部入院事件,用在线工具筛查药物间潜在相互作用并回顾病历核实临床表现。

要点

  • 烧伤合并精神共病患者中潜在严重药物相互作用常见,精神药物最常涉及。
  • 最常见持续用药为神经递质再摄取抑制类抗抑郁药和米氮平。
  • 最常见新用药为昂丹司琼、芬太尼和曲马多,潜在后果包括5-羟色胺综合征、心律失常和低钾血症。

核心结论

  • 该烧伤合并精神共病人群中潜在严重药物相互作用较多,精神药物较其他药物类别更常涉及。
  • 临床实际出现相互作用表现的证据很少,严重药物相互作用可能罕见,但临床医生应了解最可能涉及的药物及可能后果。

研究设计与样本

  • 5年单中心回顾性研究,使用国际烧伤损伤数据库识别成人区域烧伤病房有精神共病的全部入院事件。
  • 将所用药物分为新用药和持续用药,用在线工具筛查潜在相互作用,并对识别出的相互作用回顾病历核实是否临床发生。

主要发现

  • 共识别145次严重潜在相互作用,其中新药与持续药之间89次,两种新药之间56次。
  • 最常涉及相互作用的持续药物为神经递质再摄取抑制类抗抑郁药和米氮平。
  • 最常见的新药为昂丹司琼、芬太尼和曲马多。
  • 最常识别的潜在后果为5-羟色胺综合征、心律失常和低钾血症。
  • 临床上几乎没有发现任何相互作用的证据。

临床怎么用

  • 对烧伤合并精神共病患者应关注精神药物与其他药物的潜在相互作用。
  • 重点关注神经递质再摄取抑制类抗抑郁药、米氮平与昂丹司琼、芬太尼、曲马多等药物的联合使用。
  • 警惕5-羟色胺综合征、心律失常和低钾血症等潜在后果,但无需因潜在相互作用而过度限制必要用药。

局限性

  • 单中心回顾性研究,仅60份病历可用,样本量有限。
  • 依赖在线工具筛查潜在相互作用,临床实际发生证据极少,可能低估或高估临床相关性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Burns patients with psychiatric comorbidities may be at increased risk of harm from drug interactions. We aimed to identify the most common classes of drug involved, the potential clinical effects and any clinical evidence for their occurrence. METHODS: The International Burn Injury Database was used to identify all admission episodes for patients with a psychiatric comorbidity over a 5-year period at an adult regional burns unit. For this group, all drugs administered were categorised as either a new or continuing medication. Following this, an established online tool was used to screen for potential interactions between drugs. Where one was identified, a retrospective notes review was used to investigate whether it had occurred clinically. RESULTS: Ninety-one admission episodes were identified and records were available for 60 of these. In total, 145 incidences of severe potential interactions were identified (89 between a new drug and a continuing drug and 56 between two new drugs). The most frequently involved continuing drugs with the potential for interaction were neurotransmitter reuptake-inhibiting antidepressants and mirtazapine, while the most common new drugs identified were ondansetron, fentanyl and tramadol. The most frequently identified potential consequence of interactions were serotonin syndrome, arrhythmias and hypokalaemia. Clinically, there was minimal evidence for any interaction. CONCLUSION: We have found many potential severe interactions in this patient group and psychotropic drugs were more commonly implicated than other drug classes. However, there was little evidence of the clinical manifestations of interaction. Serious drug interactions in burns patients are likely rare, but clinicians should be aware of the most likely drugs involved and the possible sequelae.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Al-Khalil M, Sack A, Elson R, et al. A 5-year single-centre retrospective study of potential drug interactions in burns inpatients with psychiatric comorbidities. Burns. 2020. PMID: 32057547. doi:10.1016/j.burns.2020.01.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。